DERMANOLON 1.77 MG/ML + 17.7 MG/ML CUTANEOUS SPRAY, SOLUTION FOR DOGS AND CATS

देश: आयरलैंड

भाषा: अंग्रेज़ी

स्रोत: HPRA (Health Products Regulatory Authority)

सक्रिय संघटक:

TRIAMCINOLONE ACETONIDE, SALICYLIC ACID

थमां उपलब्ध:

Le Vet Beheer B.V.

ए.टी.सी कोड:

QD07XB02

INN (इंटरनेशनल नाम):

TRIAMCINOLONE ACETONIDE, SALICYLIC ACID

डोज़:

2.0/20.0

फार्मास्यूटिकल फॉर्म:

Cutaneous Spray Solution

प्रिस्क्रिप्शन प्रकार:

POM

चिकित्सीय समूह:

Canine, Feline

चिकित्सीय क्षेत्र:

Triamcinolone

चिकित्सीय संकेत:

Corticosteroid

प्राधिकरण का दर्जा:

Authorised

प्राधिकरण की तारीख:

2017-02-10

उत्पाद विशेषताएं

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs
and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
ACTIVE SUBSTANCES:
Triamcinolone acetonide
1.77 mg
Salicylic acid
17.7 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous spray, solution.
Clear colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Symptomatic treatment of seborrhoeic dermatitis.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to corticosteroids, salicylic
acid or to any of the excipients
Do not use on cutaneous ulcers.
Do not use in dogs with demodicosis.
Do not administer to animals weighing less than 3.5 kg body weight.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
At the beginning of treatment, existing scale and or exfoliative
debris should be removed. Hair surrounding or covering
the lesions may need to be clipped to enable the veterinary medicinal
product to reach the affected skin.
Seborrhoeic dermatitis may be a primary disorder, but can also occur
as a result of underlying disorders or disease
processes (e.g. allergic disorders, endocrine disorders, neoplasia).
Furthermore, infections (bacterial, parasitic or
fungal) commonly occur concurrently with seborrhoeic dermatitis.
Therefore it is essential to identify any underlying
disease process and initiate specific treatment if considered
necessary.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_